



SPAFID  
CONNECT

Informazione Regolamentata n. 20106-30-2021	Data/Ora Ricezione 26 Maggio 2021 09:05:22	MTA - Star
---	--	------------

Societa' : Pharmanutra S.p.A.  
Identificativo : 147830  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN02 - Lacorte Roberto  
Tipologia : 1.1; REGEM; 3.1  
Data/Ora Ricezione : 26 Maggio 2021 09:05:22  
Data/Ora Inizio : 26 Maggio 2021 09:05:23  
Diffusione presunta  
Oggetto : PR - PHN Publication of minutes of  
Shareholders' Meeting 26 04 2021

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A.: Publication of the Shareholders' Meetings minutes held on April 26, 2021.

Pisa, 26<sup>th</sup> May 2021 – [PharmaNutra S.p.A.](#) (MTA; Ticket PHN) announces that the notice of Shareholders' Meeting held on 26 April 2021 is available to the public at the Company's registered office, on the Company's website at [www.pharmanutra.it](http://www.pharmanutra.it) (section Governance/Shareholders' Meetings) and on the authorized storage system "eMarket Storage" ([www.emarketstorage.com](http://www.emarketstorage.com)).

### PharmaNutra S.p.A.

*Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative medical devices, handling the entire production process, from proprietary raw materials to the finished product. The effectiveness of its products is documented by considerable scientific proof, including 140 publications. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 39 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.*

[PharmaNutra.it](http://PharmaNutra.it)

For further information:

### PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

### Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-30

Numero di Pagine: 3